Efixan Platform of Products is in an advanced stage of development, supported by comprehensive scientific and clinical evidence. Our robust data package includes well-defined active pharmaceutical ingredients (APIs) and a clear mechanism of action (MOA). Preclinical studies, both in vitro and in vivo, have validated Efixan safety and efficacy, while field trials conducted with experienced veterinarians and the National Veterinary Hospital have demonstrated its real-world impact. Extensive safety profiles from animal studies and human clinical trials further underscore its reliability.